WO2009105048A2 - Novel applications of reconstituted hdl - Google Patents
Novel applications of reconstituted hdl Download PDFInfo
- Publication number
- WO2009105048A2 WO2009105048A2 PCT/TN2009/000002 TN2009000002W WO2009105048A2 WO 2009105048 A2 WO2009105048 A2 WO 2009105048A2 TN 2009000002 W TN2009000002 W TN 2009000002W WO 2009105048 A2 WO2009105048 A2 WO 2009105048A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hdl
- cholesterol
- carob
- almonds
- inhibitor
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 22
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 11
- 244000144725 Amygdalus communis Species 0.000 claims abstract description 4
- 240000008886 Ceratonia siliqua Species 0.000 claims abstract description 4
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims abstract description 4
- 235000020224 almond Nutrition 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 230000036772 blood pressure Effects 0.000 claims abstract description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000000047 product Substances 0.000 claims description 7
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 235000011869 dried fruits Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 235000014571 nuts Nutrition 0.000 claims description 2
- 101100181929 Caenorhabditis elegans lin-3 gene Proteins 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract description 12
- 239000004475 Arginine Substances 0.000 abstract description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract description 5
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 abstract description 4
- 239000003112 inhibitor Substances 0.000 abstract description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract description 3
- 235000018417 cysteine Nutrition 0.000 abstract description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract description 3
- 229930195712 glutamate Natural products 0.000 abstract description 3
- 150000002632 lipids Chemical class 0.000 abstract description 3
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 abstract description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 abstract description 2
- 235000001014 amino acid Nutrition 0.000 abstract description 2
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 239000002249 anxiolytic agent Substances 0.000 abstract description 2
- 229910052804 chromium Inorganic materials 0.000 abstract description 2
- 239000011651 chromium Substances 0.000 abstract description 2
- 210000003038 endothelium Anatomy 0.000 abstract description 2
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 abstract description 2
- 229960004488 linolenic acid Drugs 0.000 abstract description 2
- 230000007935 neutral effect Effects 0.000 abstract description 2
- 150000003904 phospholipids Chemical class 0.000 abstract description 2
- 230000002792 vascular Effects 0.000 abstract description 2
- 229940124549 vasodilator Drugs 0.000 abstract description 2
- 239000003071 vasodilator agent Substances 0.000 abstract description 2
- 241000758791 Juglandaceae Species 0.000 abstract 2
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 abstract 2
- 244000043158 Lens esculenta Species 0.000 abstract 2
- 235000004431 Linum usitatissimum Nutrition 0.000 abstract 2
- 240000006240 Linum usitatissimum Species 0.000 abstract 2
- 235000012041 food component Nutrition 0.000 abstract 2
- 239000005417 food ingredient Substances 0.000 abstract 2
- 235000020234 walnut Nutrition 0.000 abstract 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- -1 Pasparmate Chemical class 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000006870 function Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 1
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- HDL cholesterol has the essential role of lowering the level of bad cholesterol or LDL cholesterol.
- the proposed product is a dietary supplement that is a mixture of dried fruits or oleaginous products that can be produced industrially as a powder.
- This dried fruit mix is composed of:
- HDL cholesterol is monounsaturated, that it contains alpha linolenic acid, soluble fibers, phytoestrogens, choline.
- Arginine produces nitric oxide (NO) which performs multiple functions on the vessels as well as on the nervous and immune systems. Also NO is today considered as a kind of physiological antagonist of the sympathetic and renin angiotensin system at the level of regulation of the vascular tone Also NO:
- * is an inhibitor of platelet aggregation and leukocyte adhesion to the surface of the endothelium
Abstract
The invention relates to novel applications of HDL reconstituted from a mixture of food ingredients including almonds, walnuts, flax, carob and lentils (in powdery form) that enables: (Claim 1) a reduction in the triglyceride concentration; (Claim 2) lower blood-pressure numbers. The lipidic portion comprises phospholipids that represent 2/3 of the outer layer, and 1/3 of neutral lipids, cholesterol and triacylglycerols that form the inner portion. The proteic portion includes four amino acids, i.e. Pasparmate, glutamate, cysteine and arginine. The fact that HDL contains arginine imparts very interesting properties thereto due to the release of nitrogen monoxide (NO), which is an inhibitor of platelet build-up and of leukocyte adhesion at the surface of the endothelium, an inhibitor of smooth muscular-cell proliferation, a hypotensor acting as a potent vasodilator and a vascular relaxant. HDL further contains alphalinolenic acid (omega 3), chromium and soluble fibres. The food ingredients necessary for the production thereof are: 1) almonds, 2) flax, 3) walnuts, 4) carob, and 5) lentils.
Description
Description Description
Le HDL Cholestérol a pour rôle essentiel d'abaisser le taux du mauvais cholestérol ou LDL Cholestérol.HDL cholesterol has the essential role of lowering the level of bad cholesterol or LDL cholesterol.
Jusqu'à ce jour la recherche internationale n'a pas permis de produire le HDL CholestérolUntil now, international research has not produced HDL Cholesterol
Les nouvelles applications du HDL reconstitué a permis de mettre au jour deux nouvelles propriétés :New applications of reconstituted HDL have brought to light two new properties:
- L'abaissement du taux de triglycérides- lowering of triglycerides
- L'abaissement des chiffres tensionnels- lowering of blood pressure
Le produit proposé est un complément alimentaire qui est un mélange de fruits secs ou produits oléagineux qu'on peut produire industriellement sous forme de poudre.The proposed product is a dietary supplement that is a mixture of dried fruits or oleaginous products that can be produced industrially as a powder.
Ce mélange de fruits secs est composé de :This dried fruit mix is composed of:
- 48 % Amandes- 48% Almonds
- l l % Noix- 1% Nuts
- 22 % Lin- 22% Lin
- 3 % Caroube- 3% Carob
- 16 % Lentille- 16% Lens
On note, que le HDL Cholestérol est mono - insaturé, qu'il contient de l'acide alpha linolénique, des fibres solubles, des phyto estrogènes, de la choline.It is noted that HDL cholesterol is monounsaturated, that it contains alpha linolenic acid, soluble fibers, phytoestrogens, choline.
Il est riche en chrome.It is rich in chromium.
Concernant les lipides : ils sont constitués :Regarding lipids: they consist of:
- Pour 2/3 des phospholipides qui constituent la couche externe de HDL.- For 2/3 of the phospholipids that constitute the outer layer of HDL.
- Pour 1/3 par des lipides neutres Cholestérol et triacylglycérols qui constituent la partie interne.- For 1/3 with neutral lipids Cholesterol and triacylglycerols which constitute the internal part.
Concernant la partie protéique, elle est constituée de quatre acides aminés : a- II est riche en cystéine b- II contient de l'arginine c- Les chaînes latérales acides (asparmate et glutamate) sont prédominantes. Aussi, outre sa fonction essentielle laquelle est d'absorber le cholestérol excédentaire dans les vaisseaux sanguins, le fait de contenir de l'arginine lui confère d'autres rôles encore plus importants.
> L'arginine produit le monoxyde d'azote (NO) qui effectue de multiples fonctions sur les vaisseaux ainsi que sur les systèmes nerveux et immunitaires. Aussi le NO est aujourd'hui .considéré comme une sorte d'antagoniste physiologique du sympathique et du système rénine angiotensine au niveau de la régulation du tonus vasculaire Aussi le NO :Regarding the protein part, it consists of four amino acids: a- It is rich in cysteine b- It contains arginine c- The side chains acids (asparmate and glutamate) are predominant. Also, in addition to its essential function of absorbing excess cholesterol in the blood vessels, the fact of containing arginine gives it other roles even more important. > Arginine produces nitric oxide (NO) which performs multiple functions on the vessels as well as on the nervous and immune systems. Also NO is today considered as a kind of physiological antagonist of the sympathetic and renin angiotensin system at the level of regulation of the vascular tone Also NO:
* est un inhibiteur de l'agrégation plaquettaire et de l'adhésion leucocytaire à la surface de Pendothélium* is an inhibitor of platelet aggregation and leukocyte adhesion to the surface of the endothelium
* est un inhibiteur de la prolifération des cellules musculaires lisses* is an inhibitor of smooth muscle cell proliferation
* est un hypotenseur = agissant comme vasodilatateur puissant et un relaxant vasculaire car il entraîne dans le muscle lisse voisin une relaxation due a l'augmentation de GMPc* is a hypotensive = acting as a powerful vasodilator and a vascular relaxant because it causes relaxation in the neighboring smooth muscle due to the increase of cGMP
* est un médiateur et semble important dans le processus de mémorisation (car il est produit dans les neurones par la NOS neuronale ou n NOS)* is a mediator and seems important in the process of memorization (because it is produced in neurons by neuronal NOS or n NOS)
* est un gaz toxique qui agit pour détruire les bactéries et autres microorganismes.* is a toxic gas that acts to destroy bacteria and other microorganisms.
> Le Glutamate est soupçonné de jouer un rôle dans les fonctions> Glutamate is suspected of playing a role in functions
Cérébrales d'apprentissage et de mémorisation. Ainsi il aide à retenir les nouvelles informations et fait ressurgir les anciennes (maladie d'Alzheimer ?).Brain learning and memorizing. Thus, it helps to retain the new information and makes the old ones reappear (Alzheimer's disease?).
> La Cystéine est un anti - oxydant majeur.> Cysteine is a major antioxidant.
^ L'Asparmate joue un rôle dans l'élimination de l'ammoniaque.
Asparmate plays a role in the elimination of ammonia.
Claims
REVENDICATIONS
R 1 : le produit proposé est un complément alimentaire sous forme de poudre destiné à élever le taux de HDL Cholestérol ou Bon Cholestérol chez les diabétiques de Type 2.R 1: the proposed product is a food supplement in the form of a powder intended to raise the level of HDL Cholesterol or Good Cholesterol in Type 2 diabetics.
R 2 : le complément alimentaire selon la revendication 1 caractérisé en ce qu'il est obtenu à partir d'un mélange de fruits secs ou Oléagineux sous forme de poudre à base :R 2: the food supplement according to claim 1 characterized in that it is obtained from a mixture of dried fruits or oilseeds in powder form based on:
- 48 % Amandes- 48% Almonds
- 11 % Noix- 11% Nuts
- 22 % Lin- 22% Lin
- 3 % Caroube- 3% Carob
- 16 % Lentille- 16% Lens
R 3 : ce produit fait abaisser le taux de Triglycérides.R 3: This product lowers Triglyceride levels.
R 4 : ce produit fait abaisser les chiffres tensionnels.R 4: This product lowers blood pressure.
R 5 : ce produit élève le taux de Bon Cholestérol dans l'ordre de 50 à 70 %.R 5: this product raises the level of Bon Cholesterol in the order of 50 to 70%.
R 6 : ce produit élève le taux de Bon Cholestérol quelque soit la Pathologie qui le fait diminuer.
R 6: this product raises the rate of Bon Cholesterol, whatever the pathology that causes it to decrease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TNSN08077 | 2008-02-19 | ||
| TN08077 | 2008-02-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2009105048A2 true WO2009105048A2 (en) | 2009-08-27 |
| WO2009105048A3 WO2009105048A3 (en) | 2009-11-19 |
Family
ID=40986079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TN2009/000002 WO2009105048A2 (en) | 2008-02-19 | 2009-02-18 | Novel applications of reconstituted hdl |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2009105048A2 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004009093A1 (en) * | 2002-07-23 | 2004-01-29 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Cholesterol-reducing agent made of dietary fibre and cholesterol-reducing substances |
| WO2004066938A2 (en) * | 2003-01-28 | 2004-08-12 | University Of Georgia Research Foundation, Inc. | Method and composition for lowering cholesterol |
| EP1522310A1 (en) * | 2003-09-24 | 2005-04-13 | Nikken Sohonsha Corporation | Therapeutic uses of dunaliella powder |
| WO2009086614A1 (en) * | 2008-01-08 | 2009-07-16 | Albert Knab | Method and application of synbiotic food/feed composition for humans and animals |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01252271A (en) * | 1988-04-01 | 1989-10-06 | Matsudaira Tennenbutsu Kenkyusho:Kk | Food with lipid metabolism-improving function |
| KR100793205B1 (en) * | 2006-05-18 | 2008-01-10 | 동아대학교 산학협력단 | Health Supporting Foods for Improving Coronary Heart Diseases or Arteriosclerosis Containing an Extract of Chinese Herb as an Effective Ingredient |
-
2009
- 2009-02-18 WO PCT/TN2009/000002 patent/WO2009105048A2/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004009093A1 (en) * | 2002-07-23 | 2004-01-29 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Cholesterol-reducing agent made of dietary fibre and cholesterol-reducing substances |
| WO2004066938A2 (en) * | 2003-01-28 | 2004-08-12 | University Of Georgia Research Foundation, Inc. | Method and composition for lowering cholesterol |
| EP1522310A1 (en) * | 2003-09-24 | 2005-04-13 | Nikken Sohonsha Corporation | Therapeutic uses of dunaliella powder |
| WO2009086614A1 (en) * | 2008-01-08 | 2009-07-16 | Albert Knab | Method and application of synbiotic food/feed composition for humans and animals |
Non-Patent Citations (6)
| Title |
|---|
| DATABASE CAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002547396 extrait de STN Database accession no. 1995:181195 * |
| DATABASE FSTA [Online] INTERNATIONAL FOOD INFORMATION SERVICE (IFIS), FRANkFURT-MAIN, DE; 2003, MORGAN J M ET AL: "Effects of walnut consumption as part of a low-fat, low-cholesterol diet on serum cardiovascular risk factors." XP002547397 Database accession no. 2003-00-j0452 & INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH, 2002, 72 (5) 341-347 2002 DEP. OF MED., THOMAS JEFFERSON UNIV., PHILADELPHIA, PA 19107, USA * |
| DATABASE WPI Thomson Scientific, London, GB; AN 2008-F24441 XP002547399 & KR 2007 111 624 A (HAN ET AL) 22 novembre 2007 (2007-11-22) * |
| DATABASE WPI Week 198946 Thomson Scientific, London, GB; AN 1989-337020 XP002547398 & JP 01 252271 A (MATSUDAIRA TENNENBU) 6 octobre 1989 (1989-10-06) * |
| HYSON ET AL.: "Almonds and almond oil have similar effects on plasma lipids and LDL oxidation in healthy men and women" JOURNAL OF NUTRITION, vol. 132, no. 4, 2002, pages 703-707, XP008112582 * |
| TEOTIA ET AL.: "Effect of Prunus amygdalus seeds on lipid profile" NDIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, vol. 41, no. 4, 1997, pages 383-389, XP008112578 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009105048A3 (en) | 2009-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2721890B2 (en) | Method for extracting polyunsaturated fatty acid esters from fish oil | |
| ES2837104T3 (en) | Very long chain polyunsaturated fatty acids from natural oils | |
| RU2480474C2 (en) | Mixtures of polar lipids, production and use thereof | |
| EP2068637B1 (en) | Milk ingredient enriched in polar lipids and uses thereof | |
| CN113845566B (en) | Walnut polypeptide for preventing Alzheimer's disease and application thereof | |
| EP3353191B1 (en) | Cyclic polypeptides, method for obtaining said polypeptides and the therapeutic use thereof | |
| WO2011078204A1 (en) | Prophylactic or therapeutic agent for hyperlipemia, and anti-fatigue agent | |
| WO1994012170A2 (en) | Polyunsaturated fatty acid based drugs, in particular docosahexaenoic acid, for use as platelet aggregation inhibitors and against essential fatty acid deficiencies of the brain | |
| JP2018070632A (en) | Rice bran enzyme treatment composition | |
| AU2015205525A1 (en) | Phospholipid compositions and their preparation | |
| WO2009105048A2 (en) | Novel applications of reconstituted hdl | |
| ATE424732T1 (en) | PREPARATIONS CONTAINING POLYUNSATURATED PHOSPHOLIPIDES, MONOTERPENES AND TRYPTOPHAN AND/OR PHYTOL DERIVATIVES | |
| HUE030753T2 (en) | Dha enrichment process | |
| KR20080011678A (en) | Process for the preparation and isolation of phosphatides | |
| EP2091553B1 (en) | Casein-derived peptides having anxiolytic activity | |
| JP5799842B2 (en) | Angiotensin converting enzyme inhibitory peptide, angiotensin converting enzyme inhibitor containing the peptide, composition and food, and method for producing the peptide | |
| EP2300039B1 (en) | ANXIOLYTIC COMPOSITION CONTAINING ALPHAs¹-CASEIN -DERIVED PEPTIDES | |
| DE60216523T2 (en) | PREPARATION AND USE OF SOY PROTEIN HYDROLYSATES ENRICHED WITH BRANCHED AMINO ACIDS | |
| CA2628304A1 (en) | Method of refining episesamin | |
| JP2012206958A (en) | Vascular endothelial function improving agent | |
| CN100344767C (en) | Rich alpha-linolenic acid contained polyene phosphatidylcholine and its production method | |
| ITUB20153877A1 (en) | Method of purification of glycerides of fatty acids, compositions derived from them, and their use | |
| JP2004536062A5 (en) | ||
| WO2011046522A2 (en) | Novel uses of reconstituted free testosterone | |
| RU2368249C1 (en) | Phospholipidic biologically active supplement for food with hypotensive properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 09713215 Country of ref document: EP Kind code of ref document: A2 |